

# Aaron R Hansen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3527322/aaron-r-hansen-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

195  
papers

8,227  
citations

38  
h-index

89  
g-index

222  
ext. papers

11,263  
ext. citations

4.8  
avg, IF

6.19  
L-index

#	Paper	IF	Citations
195	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , <b>2019</b> , 394, 1915-1928	40	839
194	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1-10	2.2	786
193	Tumour heterogeneity in the clinic. <i>Nature</i> , <b>2013</b> , 501, 355-64	50.4	770
192	Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 543-50	2.2	454
191	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 440-451	21.7	448
190	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2377-2385	10.3	372
189	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 836-45	2.2	279
188	Overview of the 8th Edition TNM Classification for Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , <b>2017</b> , 18, 40	5.4	261
187	Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4050-4056	2.2	211
186	Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. <i>Oral Oncology</i> , <b>2013</b> , 49, 79-85	4.4	193
185	Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 82, 276-83	4	171
184	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1807-1813	10.3	165
183	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , <b>2016</b> , 8, 109	14.4	149
182	Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking. <i>Nature Nanotechnology</i> , <b>2017</b> , 12, 274-281	28.7	149
181	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 103, 49-56	5.3	142
180	A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1824-1829	10.3	139
179	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 2190-2198	7.5	107

178	Point-of-care outcome assessment in the cancer clinic: audit of data quality. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 95, 339-43	5.3	89
177	PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. <i>JAMA Oncology</i> , <b>2016</b> , 2, 15-6	13.4	84
176	Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 1078-85	4	79
175	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , <b>2019</b> , 125, 1341-1349	6.4	78
174	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky021	4.6	73
173	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , <b>2016</b> , 18, 128-36	8.1	66
172	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , <b>2016</b> , 30, 571-584	7.9	66
171	Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. <i>Journal of Urology</i> , <b>2018</b> , 200, 126-135	2.5	65
170	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 340-352	4	64
169	Early phase clinical trials to identify optimal dosing and safety. <i>Molecular Oncology</i> , <b>2015</b> , 9, 997-1007	7.9	59
168	Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>Cancer</i> , <b>2017</b> , 123, 3691-3700	6.4	57
167	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 773-785	7.4	53
166	The microbiome and cancer for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 141, 1-12	7	50
165	Phase 1 trial design: is 3 + 3 the best?. <i>Cancer Control</i> , <b>2014</b> , 21, 200-8	2.2	47
164	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , <b>2016</b> , 67, 174-182	7.5	46
163	A comprehensive review of immunotherapies in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 113, 292-303	7	43
162	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 1113-1119	8.7	42
161	Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 98, 159-169	4	41

160	Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma. <i>Cell Reports</i> , <b>2018</b> , 25, 1318-1331.e4	10.6	41
159	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , <b>2019</b> , 76, 861-867	10.2	39
158	Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1743-1752	8.7	38
157	Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus-Mediated Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 1017-1027	4	38
156	The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre. <i>Cancer Epidemiology</i> , <b>2013</b> , 37, 820-9	2.8	35
155	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. <i>European Urology</i> , <b>2017</b> , 71, 120-127	10.2	34
154	Comparison of Health State Utility Measures in Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2015</b> , 141, 696-703	3.9	34
153	Radiologic-Pathologic Correlation of Extranodal Extension in Patients With Squamous Cell Carcinoma of the Oral Cavity: Implications for Future Editions of the TNM Classification. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 698-708	4	34
152	Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. <i>Oral Oncology</i> , <b>2016</b> , 54, 75-80	4.4	32
151	Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 1107-1116	4	30
150	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 32918-32929	3.3	30
149	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1919-1926	2.2	29
148	Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101874	2.2	27
147	Structure and Optimization of Checkpoint Inhibitors. <i>Cancers</i> , <b>2019</b> , 12,	6.6	27
146	Mitosis trumps T stage and proposed international association for the study of lung cancer/american thoracic society/european respiratory society classification for prognostic value in resected stage 1 lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 673-81	8.9	25
145	Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 97, 709-717	4	25
144	A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 258-66	12.9	24
143	Challenges in establishing the diagnosis of human papillomavirus-related oropharyngeal carcinoma. <i>Laryngoscope</i> , <b>2016</b> , 126, 2270-5	3.6	24

142	Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma. <i>Head and Neck</i> , <b>2016</b> , 38, 1347-53	4.2	24
141	Morphologic and topographic radiologic features of human papillomavirus-related and -unrelated oropharyngeal carcinoma. <i>Head and Neck</i> , <b>2017</b> , 39, 1524-1534	4.2	23
140	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , <b>2020</b> , 108, 104736	4.4	23
139	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2021869	10.4	23
138	Primary surgery versus (chemo)radiotherapy in oropharyngeal cancer: the radiation oncologist <sup>Q</sup> and medical oncologist <sup>Q</sup> perspectives. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , <b>2015</b> , 23, 139-47	2	20
137	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , <b>2019</b> , 108, 69-77	7.5	20
136	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , <b>2020</b> , 126, 3426-3437	6.4	19
135	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1563-1574	2.2	19
134	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , <b>2019</b> , 2, 643-648	6.7	19
133	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. <i>Oncologist</i> , <b>2015</b> , 20, 653-9	5.7	18
132	Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated Ranking. <i>Analytical Chemistry</i> , <b>2019</b> , 91, 9348-9355	7.8	18
131	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , <b>2019</b> , 24, 1188-1194	5.7	17
130	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 144, 13-22	5.3	17
129	Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 98, 186-195	4	16
128	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) <b>2019</b> , 7, 72		16
127	Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 1465-1474	7.5	15
126	Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2016</b> , 142, 1208-1215	3.9	15
125	Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. <i>Cancer Research</i> , <b>2018</b> , 78, 5398-5407 <sup>10.1</sup>		15

124	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , <b>2021</b> , 4, 102-111	6.7	15
123	Partial Laryngeal IMRT for T2N0 Glottic Cancer: Impact of Image Guidance and Radiation Therapy Intensification. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 941-949	4	14
122	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , <b>2019</b> , 24, e146-e148	5.7	14
121	Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 99, 858-867	4	13
120	Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 858-67	12.9	13
119	Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R97	8.3	13
118	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1553-1562	2.2	13
117	The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer. <i>Seminars in Radiation Oncology</i> , <b>2018</b> , 28, 17-26	5.5	13
116	Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire. <i>Cancer</i> , <b>2020</b> , 126, 4042-4050	6.4	12
115	A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. <i>Oral Oncology</i> , <b>2016</b> , 59, 43-49	4.4	12
114	The interplay of IMRT and transoral surgery in HPV-mediated oropharyngeal cancer: Getting the balance right. <i>Oral Oncology</i> , <b>2018</b> , 86, 171-180	4.4	12
113	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 54, 43-57	14.4	11
112	Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. <i>European Urology Oncology</i> , <b>2021</b> , 4, 483-491	6.7	11
111	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. <i>Clinical and Translational Radiation Oncology</i> , <b>2019</b> , 17, 32-39	4.6	10
110	Treatment implications of postoperative chemoradiotherapy for squamous cell carcinoma of the oral cavity with minor and major extranodal extension. <i>Oral Oncology</i> , <b>2020</b> , 110, 104845	4.4	10
109	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. <i>JCO Clinical Cancer Informatics</i> , <b>2018</b> , 2, 1-12	5.2	10
108	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , <b>2019</b> , 123, 138-145	7.5	9
107	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , <b>2020</b> , 126, 1550-1558	6.4	9

106	A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , <b>2020</b> , 13, 1178-1188	4.9	9
105	Hypopharyngeal cancer: looking back, moving forward. <i>Current Oncology</i> , <b>2016</b> , 23, 221-2	2.8	9
104	Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies. <i>Hormones and Cancer</i> , <b>2020</b> , 11, 155-169	5	9
103	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, 59-66	1.2	8
102	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 11002-11002	2.2	8
101	A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6045-6045	2.2	8
100	Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. <i>European Urology Oncology</i> , <b>2019</b> , 2, 437-442	6.7	8
99	Postoperative wound infections, neutrophil-to-lymphocyte ratio, and cancer recurrence in patients with oral cavity cancer undergoing surgical resection. <i>Oral Oncology</i> , <b>2019</b> , 97, 23-30	4.4	7
98	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 980-988	9.7	7
97	Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 3015-3022	4.8	6
96	Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer. <i>Head and Neck</i> , <b>2020</b> , 42, 2277-2286	4.2	6
95	Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2016</b> , 12, e222-8	1.9	6
94	Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancer. <i>Head and Neck</i> , <b>2020</b> , 42, 513-521	4.2	6
93	Assessment Criteria and Clinical Implications of Extranodal Extension in Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2021</b> , 41, 265-278	7.1	6
92	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , <b>2016</b> , 34, 575-83	4.3	6
91	Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2166-2174	7.5	6
90	Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. <i>Oral Oncology</i> , <b>2021</b> , 114, 105167	4.4	6
89	Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 135, 76-84	7	5

88	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. <i>Oncologist</i> , <b>2020</b> , 25, 422-430	5.7	5
87	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , <b>2019</b> , 118, 112-120	7.5	5
86	Finding/identifying primaries with neck disease (FIND) clinical trial protocol: a study integrating transoral robotic surgery, histopathological localisation and tailored deintensification of radiotherapy for unknown primary and small oropharyngeal head and neck squamous cell carcinoma. <i>BMJ Open</i> , <b>2019</b> , 9, e035431	3	5
85	Pre- and Post-Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. <i>Laryngoscope</i> , <b>2021</b> , 131, E1162-E1171	3.6	5
84	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , <b>2017</b> , 123, 1409-1415	4.15	4
83	Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222359	3.7	4
82	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	4
81	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. <i>Cancer</i> , <b>2021</b> , 127, 2587-2594	6.4	4
80	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study <b>2021</b> , 9,		4
79	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , <b>2021</b> , 10, 1212-1221	4.8	4
78	Principles of cancer staging	34-39	4
77	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 848.e1-848.e7	2.8	3
76	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , <b>2020</b> , 105, 104666	4.4	3
75	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. <i>BJU International</i> , <b>2018</b> , 122, 814-822	5.6	3
74	Surgery- vs Radiation-Based Therapy for p16+/HPV-Related Oropharyngeal Cancers. <i>Current Otorhinolaryngology Reports</i> , <b>2018</b> , 6, 298-309	0.5	3
73	HPV Status Improves Classification of Head and Neck Gray Zone Cancers. <i>Journal of Dental Research</i> , <b>2019</b> , 98, 879-887	8.1	3
72	Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option. <i>European Urology Focus</i> , <b>2019</b> , 5, 702-703	5.1	3
71	Role of the oral and gut microbiota as a biomarker in locoregionally advanced oropharyngeal squamous cell carcinoma (ROMA LA-OPSCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 6045-6045	2.2	3



70	First-in-class microbial ecosystem therapeutics 4 (MET4) in metastatic solid cancer patients treated with immunotherapy: MET4-IO.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3098-3098	2.2	3
69	Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5063-5063	2.2	3
68	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 642-642	2.2	3
67	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkaa115	4.6	3
66	Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2021</b> , 161, 856-868.e1	1.5	3
65	First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. <i>Annals of Oncology</i> , <b>2018</b> , 29, viii404	10.3	3
64	Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy. <i>Oral Oncology</i> , <b>2019</b> , 97, 124-130	4.4	2
63	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1753-1768	3.8	2
62	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz071	4.6	2
61	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5071-5071	2.2	2
60	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , <b>2020</b> , 9, 337	3.6	2
59	Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 684-684	2.2	2
58	Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. <i>Journal of Cancer Metastasis and Treatment</i> , <b>2020</b> , 6,	3.8	2
57	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 165, 94-102	5.3	2
56	Dual Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancer: Just a Gambit or Real CheckMate?. <i>Cancer Cell</i> , <b>2020</b> , 38, 438-440	24.3	2
55	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. <i>Urology</i> , <b>2020</b> , 138, 69-76	1.6	2
54	Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies. <i>Cancer</i> , <b>2021</b> , 127, 1360-1368	6.4	2
53	Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review. <i>Cancer Medicine</i> , <b>2021</b> , 10, 5031-5040	4.8	2

52	Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2114694	10.4	2
51	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , <b>2021</b> , 10, 5775-5782	4.8	2
50	Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. <i>Annals of Oncology</i> , <b>2018</b> , 29, viii315	10.3	2
49	Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. <i>Clinical and Translational Radiation Oncology</i> , <b>2020</b> , 21, 69-76	4.6	1
48	Reply to J.J. Beitler et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3218-9	2.2	1
47	Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma.. <i>Oral Oncology</i> , <b>2022</b> , 125, 105716	4.4	1
46	A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3057-3057	2.2	1
45	Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6586-6586	2.2	1
44	Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts. <i>International Journal of Cancer</i> , <b>2021</b> ,	7.5	1
43	Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers. <i>Cancer</i> , <b>2021</b> ,	6.4	1
42	A New Staging System for HPV-Related Oropharynx Cancer: Rationale, Derivation, Validation and Practical Applications <b>2018</b> , 149-164		1
41	Mapping PRO-CTCAE responses to clinician-graded adverse events, dose reductions, interruptions, and discontinuations in phase I cancer trials.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2014-2014	2.2	1
40	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e350-e359	3.3	1
39	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, 84-97	1.2	1
38	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 157, 255-262	5.3	1
37	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 354-361	3.3	1
36	Out-of-pocket costs associated with head and neck cancer treatment. <i>Cancer Reports</i> , <b>2021</b> , e1528	1.5	1
35	Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 224-224	2.2	1

34	Daily symptom monitoring commonly leads to treatment modification in older adults receiving treatment for metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 82-82	2.2	1
33	Radiologic-pathologic correlation of major versus minor extranodal extension in oral cavity cancer.. <i>Head and Neck</i> , <b>2022</b> ,	4.2	1
32	Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer.. <i>Cancer Medicine</i> , <b>2021</b> ,	4.8	1
31	Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E537-E542	1.2	0
30	Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel.. <i>Oncologist</i> , <b>2022</b> , 27, 4-6	5.7	0
29	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259272	3.7	0
28	Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa050	4.6	0
27	Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , <b>2021</b> , 5, 21-29	0.6	0
26	Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp $\square$ in combination with atezolizumab $\square$ bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4556-4556	2.2	0
25	Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 6081-6081	2.2	0
24	Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e15038-e15038	2.2	0
23	Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 79, 177-179	10.2	0
22	Construct Validity of the EuroQoL-5 Dimension and the Health Utilities Index in Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2021</b> , 1945998211030173	5.5	0
21	Risk Stratification of HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Are All Tumors Created Equally?. <i>Current Otorhinolaryngology Reports</i> , <b>2022</b> , 10, 68	0.5	
20	Salvage chemotherapy for metastatic germ cell tumours: The known unknowns. <i>Canadian Urological Association Journal</i> , <b>2012</b> , 6, 117-8	1.2	
19	Barriers and facilitators to implementation of serial point-of-care hearing tests using a novel iPad-based audiometry in platinum chemotherapy-treated cancer patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 223-223	2.2	
18	An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 283-283	2.2	
17	An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e19303-e19303	2.2	

16	Persistence of platinum in semen of cisplatin-treated survivors of advanced testicular cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5056-5056	2.2
15	Phase I Study Methodology in Head and Neck Oncology <b>2016</b> , 731-742	
14	Treatment of Viral-Associated HNC (OPC and NPC) <b>2017</b> , 177-188	
13	Human Papillomavirus and Head and Neck Cancer <b>2018</b> , 167-181	
12	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 469-472	3.5
11	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , <b>2019</b> , 24, e518-e525	5.7
10	Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies.. <i>JCO Precision Oncology</i> , <b>2018</b> , 2, 1-20	3.6
9	Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma <b>2021</b> , 119-137	
8	Comparison of patients with high-risk nonmetastatic clear cell renal carcinoma in adjuvant therapy trials versus nonclinical trial patients.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 361-361	2.2
7	The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 333-333	2.2
6	Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 316-316	2.2
5	Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 346-346	2.2
4	Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 304-304	2.2
3	Genomic characterization and identification of actionable variants in patients with locally advanced or metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 562-562	2.2
2	The role of cytoreductive nephrectomy and systemic therapy in the management of tumor thrombus in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 345-345 <sup>2</sup>	2.2
1	Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 332-332	2.2